The assessment tools contained in this Application ("Assessment Tools") are intended only to be an informational tool for clinicians who have been allowed access to the Application by BI. The Assessment Tools are not intended to provide general or specific medical advice. The Assessment Tools do not take into account other considerations including, but not limited to, drug interactions, contraindications and patient history, and other risk factors. Therefore, the Application and Assessment Tools should be used as a general guide only and any specific advice provided by clinicians should be based on a professional review and consideration of each patient.
In cases of emergency surgery or urgent procedures1:
When the rapid reversal of the anticoagulant effect of Pradaxa is required (for patients who required that can not be delayed for at least 8 hours and for which normal haemostatis is desirable)2, the specific reversal agent (PRAXBIND®, idarucizumab) to PRADAXA® is available.1
Depending on the clinical condition of the patient, coagulation testing can be of value to determine the presence or absence of circulating dabigatran.2
The aPTT test may be useful in determining an excess of anticoagulant activity. Dabigatran concentration exceeding 450-500 ng/mL would result in an aPTT of greater than 2.5 times control. An aPTT greater than 2.5 times control is suggestive of excess anticoagulation.
The TT test can determine the presnse or absence of dabigatran in the circulation and, together with an aPTT, may also be useful.2
1. PRAXBIND Approved Product Information, 14 January 2022.
2. Eikelboom J et al. Idarucizumab. The Antidote for Reversal of Dabigatran, Circulation. 2015;132:2412-2422
Notification Title